| abstract |
The present invention relates to the development of a recombinant immunotoxin in which an RNA degrading enzyme (ribonuclease, RNase) is fused to a cytoplasmic penetrating antibody that penetrates into the cytoplasm of a target cell. More specifically, (Cytotransmab, CT), which infiltrates into the cytoplasm by endosomal cleavage, and a human-derived RNase that lacks cytoplasmic infiltration ability, to produce a new recombinant cytoplasm that can transfer RNase into the cytoplasm of the target cell RNase (CT-RNase, CT-R) immunotoxin, its preparation method and use. The cytotoxic infiltrating antibody-RNase immunotoxin according to the present invention infiltrates into the cytoplasm of the target tumor cells and shows cytotoxicity due to RNase activity, thereby inhibiting tumor growth and inducing apoptosis. The pharmaceutical composition for treating and preventing tumor . |